As of November 14, 2026, Acurx Pharmaceuticals, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 9, 2026 to November 13, 2026 (Form 8-K, November 13, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Acurx Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Acurx Pharmaceuticals, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-09 to 2026-11-13. Every row below is cited to the filing it comes from, and this page adds each new change as Acurx Pharmaceuticals, Inc. files it.
Also on the record for Acurx Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 29, 2026 | Form D, private offering | $4.59M sold | Form D page | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G, by Armistice Capital, LLC | 8.7% of the class | 5%+ stakes | Source |
| June 27, 2025 | Form D, private offering | $3.98M sold | Form D page | Source |
| May 20, 2025 | Form D, private offering | — | Form D page | Source |
| March 21, 2025 | Form D, private offering | $3.38M sold | Form D page | Source |
| January 17, 2025 | Form D, private offering | $2.40M sold | Form D page | Source |
Selling to them or working with them? See who runs Acurx Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Acurx Pharmaceuticals, Inc. and the records around it.
Acurx Pharmaceuticals, Inc. elsewhere on the record
- Company profile and every filing Apr 2026
- Form D filing Apr 2026
- Form D filing Jun 2025
- Who owns it
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Acurx Pharmaceuticals, Inc.
Get an email when Acurx Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Acurx Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Acurx Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Acurx Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-13 | Reported | not named in the filing | 8-K, 2026-11-13 | ||
| 2026-03-09 | Reported | not named in the filing | 8-K, 2026-03-09 |
New leaders reset buying decisions — get the Full Report on Acurx Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Acurx Pharmaceuticals, Inc. (free up to 3)
Find people with the same kind of experience as the senior executive at Acurx Pharmaceuticals, Inc., with the record behind each one.
Find candidates like senior executive at Acurx Pharmaceuticals, Inc.Every change, in the filing's words
Reported
Mr. Scodari's retirement follows years of dedicated service, leadership and significant contributions to the Company and to the healthcare and pharmaceutical industries.
- On November 12, 2026, Joseph C. Scodari, a member of the Board of Directors (the "Board") of Acurx Pharmaceuticals, Inc. (the "Company") since 2021, provided the Company with notice of his intention to retire from the Board, effective November 13, 2026.
- Mr. Scodari's decision did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Following his retirement from the Board, Mr. Scodari has agreed to continue to serve the Company as a corporate advisor.
Reported
The Director Cash Reductions will become effective as of April 1, 2026.
- On March 9, 2026, the Compensation Committee of the Board of Directors (the "Compensation Committee") of Acurx Pharmaceuticals, Inc. (the "Company") approved, and the executive officers listed below voluntarily agreed to, reductions to their base salaries (the "Salary Reductions") as part of broader leadership compensation alignment measures.
- The Compensation Committee also approved a 10% reduction to the cash components of the Company's non-employee director compensation program, including annual cash retainers for Board service and additional cash retainers for the Chair of the Board and for committee chairs and members (the "Director Cash Reductions").
- Under the Salary Reductions, effective as of April 1, 2026, the base salaries of the following executives will be: Executive Title Annual Base Salary After 10% Reduction David P. Luci President and Chief Executive Officer $495,000 Robert J. DeLuccia Executive Chairman $495,000 Robert G. Shawah Chief Financial Officer $360,000 The Salary Reductions are being implemented on a fully voluntary basis at the request of the executives and were approved by the Compensation Committee following its review of market conditions and the Company's operating plan.
- The Salary Reductions do not modify the terms of any executive's employment agreement other than with respect to base salary.
Acurx Pharmaceuticals, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Acurx Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
